Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021
HomeW. L. Gore & Associates Inc.GORE® EXCLUDER® Iliac Branch Endoprosthesis Approved in Japan

GORE® EXCLUDER® Iliac Branch Endoprosthesis Approved in Japan

Takao Ohki, MD, PhD, Chairman and Professor of the Department of Surgery at Jikei University School of Medicine in Tokyo, who successfully performed the first two implants in Japan, said, “Providing a simple and straightforward procedure, the IBE preserves flow to the internal iliac arteries during EVAR. He went on to say, “In many patients, it is imperative that iliac artery blood flow be maintained when possible to avoid complications that can result when these arteries are sacrificed. The IBE will not only reduce complications but also expand the indication for less invasive endovascular treatment for patients that were rejected due to the inability to preserve internal iliac arteries. This is excellent news for Japanese patients.”

Takao Ohki, MD, PhD, Chairman and Professor of the Department of Surgery at Jikei University School of Medicine in Tokyo, who successfully performed the first two implants in Japan, said, “Providing a simple and straightforward procedure, the IBE preserves flow to the internal iliac arteries during EVAR. He went on to say, “In many patients, it is imperative that iliac artery blood flow be maintained when possible to avoid complications that can result when these arteries are sacrificed. The IBE will not only reduce complications but also expand the indication for less invasive endovascular treatment for patients that were rejected due to the inability to preserve internal iliac arteries. This is excellent news for Japanese patients.”

W. L. Gore & Associates, Inc. (Gore) announced the first implants in Japan of the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE). Gore reported that they have received Shonin approval from the Japanese Ministry of Health, Labour and Welfare to market the IBE and is currently in discussion regarding reimbursement for this region. The IBE is the first off-the-shelf iliac branch solution approved in Japan and the only device indicated for the endovascular treatment of common iliac artery aneursyms or aortoiliac aneursyms.

With more than 2,500 commercial implants worldwide, the device is a complete, fully engineered system (Gore designed iliac branch and internal iliac components), which received CE Mark in 2013, registration in Australia and New Zealand in 2015, and FDA and Health Canada approval in 2016.

Used in conjunction with the GORE® EXCLUDER® AAA Endoprosthesis, the IBE preserves blood flow in the external and internal iliac arteries. The IBE leverages the design and experience acquired from more than 20 years and 285,000 patients treated* with the GORE EXCLUDER AAA Endoprosthesis and utilizes the same durable, expanded polytetrafluoroethylene (ePTFE) graft and nitinol stent material. The IBE offers an All-in-One System with improved outcomes for the treatment of iliac artery aneurysms while preserving flow to the iliac arteries. Preservation of blood flow in the internal iliac arteries is found to avoid pelvic flow disruption and reduce the rate of complications that can include buttock claudication, sexual dysfunction, and colonic ischemia.

Takao Ohki, MD, PhD, Chairman and Professor of the Department of Surgery at Jikei University School of Medicine in Tokyo, who successfully performed the first two implants in Japan, said, “Providing a simple and straightforward procedure, the IBE preserves flow to the internal iliac arteries during EVAR.  He went on to say, “In many patients, it is imperative that iliac artery blood flow be maintained when possible to avoid complications that can result when these arteries are sacrificed. The IBE will not only reduce complications but also expand the indication for less invasive endovascular treatment for patients that were rejected due to the inability to preserve internal iliac arteries. This is excellent news for Japanese patients.”

The IBE system provides a treatment range of 6.5-13.5 mm for the internal iliac arteries, and a treatment range of 6.5-25 mm for the external iliac arteries. The delivery profile of the loaded catheter allows the use of a 16 Fr introducer sheath for the iliac branch component, and a flexible 12 Fr, reinforced introducer sheath for the internal iliac component.

Eric Zacharias, Vascular Business Leader added, “We are pleased to receive approval of this device in regions worldwide as it continues to provide an iliac branch solution for a patient group with a previously unmet treatment need.  Together with physicians, we have spent the past 20 years determining patient needs and continually working to improve our aortic family of devices to provide solutions physicians trust and patients count on.”  Zacharias concluded, “The IBE is an exciting innovation that stems from our mission to effectively treat aortic aneurysms through minimally invasive means.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy